As you have pointed out previously Dr. M.'s strength is finance and directing very clever ways for getting trial funds/sponsors. Rett/MS-Sweden-WSU studies/MJFF/AUS-small trials for FDA. I predict AVXL will get funds for AD from somewhere NIH Grants or elsewhere.
The other good news is he has developed a rationale around precision medicine which fits well w/technical strengths and smaller trial populations. I still believe the RETT trial will become the poster child on structure and results.
The other news is, when you are a small fish...you are a small fish. If we keep alive, we will be taken shortly, IMO. If A2-73 and platform is anywhere near as good as claimed then being taken seems certain.